Optional H2 Subhead

Provider Update January 2026

Welcome to our new Update Newsletter format where information for our medical, dental and Medicare Advantage products is included in one publication. 

General information

Action required – Digital-first preauthorization submissions transition for pharmacy

To streamline administrative workflows, improve processing timeliness and enhance overall care delivery efficiency, BCBSNE will transition to accepting pharmacy drug preauthorization requests exclusively through our digital tools starting Dec. 15, 2025. This change applies to pharmacy preauthorizations for our commercial lines of business.

What’s changing?
BCBSNE is making it easier for providers to manage drug preauthorizations (PAs) with improved experiences available through CoverMyMeds. Key benefits include:

  • Real-time eligibility checks to confirm coverage before submitting
  • Electronic PA submissions - no more faxing paper forms
  • Immediate confirmation of receipt - no need to call or resubmit
  • Faster processing and reduced administrative burden

How to submit?

  • Participating providers: Use CoverMyMeds via NaviNet, our provider portal.
  • Out-of-network or providers outside Nebraska: If you do not have access to CoverMyMeds via NaviNet, you may access CoverMyMeds through the Providers Preauthorization page.

Action items:

  • Register for NaviNet if you haven’t already
  • Continue monitoring Happening Now and our Provider Bulletin for updates

Jan. 5, 2026 – Pharmacy drug prior authorization status will only be available using digital tools

  • CoverMyMeds (if the request was submitted through CoverMyMeds)
  • Online preauthorization platform, if the form was used
  • Automated phone system (CSC will not be available)

Fax line retirement
Effective Dec. 15, 2025, the following prior authorization fax numbers will be retired:

  • Pharmacy: 1-877-232-6726 or 402-548-4683

Important:

  • Faxes submitted before Dec. 15 will receive a response notifying you of the upcoming change.
  • After Dec. 15, commercial pharmacy preauthorization requests sent to any BCBSNE fax number will not be processed. Providers will receive a faxed response indicating the request was misrouted.

What’s not changing

Watch Happening Now for updates to these forms and our Pharmacy Management page.

We appreciate your partnership as we move toward more efficient, digital-first solutions to support you and your patients.

Urgent preauthorization updates to post at the top of our preauthorizations page

To ensure providers receive timely and critical updates, we will begin posting urgent communications at the top of our Preauthorization page.

This section will serve as a dedicated space for high-priority messages, including changes that may affect processing times, documentation requirements or system functionality. This approach is designed to make urgent information easy to find and reduce delays in patient care.

Providers are encouraged to check our Preauthorization page regularly and review any notices posted at the top of the page. These updates will be concise and focused on actions that require immediate attention.

Medical Records Retrieval Project for HEDIS®

Medical Record Review Period: January – May 2025
Each year, Blue Cross and Blue Shield of Nebraska (BCBSNE) conducts medical record reviews from February through May to collect essential data for HEDIS® (Healthcare Effectiveness Data and Information Set) reporting. These reviews help us assess the quality of care provided to our members and identify opportunities for improvement.

What to Expect
BCBSNE partners with Reveleer, our medical record retrieval vendor, to coordinate outreach to provider offices during the annual HEDIS® review period. Your clinic may receive requests for specific clinical information not available through claims data. These requests may include:

  • Blood pressure readings
  • HbA1c lab results
  • Colorectal cancer screening documentation
  • Transitions of Care records, including:
    • Post-discharge medication reconciliation
    • Admission and discharge summaries to confirm provider notification

Your timely response is essential to support accurate quality reporting and improve patient outcomes.
 
Provider Responsibilities
As a participating provider, your contract includes provisions requiring you to supply requested medical records to BCBSNE or its designated third-party vendors at no cost. We strive to minimize disruption to your workflow and appreciate prompt responses to avoid repeated follow-ups.

Why It Matters
Your support in this initiative helps us:

  • Meet HEDIS® quality measurement goals
  • Ensure accurate reporting
  • Improve the health and well-being of our members, your patients
New Medical Policies Effective March 2026

Starting in March 2026, new medical policies will go into effect for both Commercial and Medicare Advantage plans. In February 2026, revisions to existing medical policies will also take effect. To ensure a smooth transition and minimize any disruption to your current processes, please review the updated policies below.

MA new polices effective March 1, 2026

  • Amniotic Membrane and Amniotic Fluid
    • Policy number: M.14
    • Summary: Amniotic membrane is covered for specific eye and wound conditions (e.g., diabetic ulcers, corneal ulcers), but amniotic fluid injections are not medically necessary for any indication.
  • Benign Prostate Hyperplasia
    • Policy number: M.29
    • Summary: Covers specific minimally invasive treatments for BPH—such as prostatic urethral lift (Urolift), water vapor therapy (Rezum), and transurethral waterjet ablation—when strict clinical criteria are met, while deeming other procedures (e.g., PAE, cryoablation, HIFU) not medically necessary.
  • Single Chamber and Dual Chamber Permanent Cardiac Pacemaker and Defibrillators
    • Policy number: M.30
    • Summary: Covers permanent pacemakers for symptomatic bradycardia and implantable cardioverter defibrillators (ICDs) for specific high-risk cardiac conditions per CMS NCD criteria, while excluding reversible causes and non-indicated uses.
  • Electrophysiology Testing and Cardiac Ablation
    • Policy number: M.31
    • Summary: Coverage for electrophysiology (EP) testing and cardiac ablation is based on InterQual criteria to determine medical necessity for diagnostic and therapeutic procedures.
  • Non-Coronary Vascular Stents
    • Policy number: M.32
    • Summary: Coverage for non-coronary vascular stent procedures is based on CMS LCD criteria (L35998 and A57590) to determine medical necessity for vascular interventions.
  • Cardiac Catheterization
    • Policy number: M.33
    • Summary: Covers right, left, or combined heart catheterization when clinically indicated for diagnosis or treatment planning of cardiac conditions, while excluding non-indicated uses such as routine angioplasty or electrophysiologic studies.
  • Orthognathic Surgery
    • Policy number: M.34
    • Summary: Covers orthognathic surgery for correction of skeletal deformities causing functional impairment when strict clinical criteria are met, and for obstructive sleep apnea after failure of CPAP; excludes cosmetic indications and procedures lacking proven effectiveness.
  • Urinary Incontinence Treatment
    • Policy number: M.35
    • Summary: Allows periurethral bulking agent injections for stress urinary incontinence meeting specific criteria, while deeming adjustable balloon continence devices and other non-proven treatments not medically necessary.
  • Non-invasive Cerebrovascular and Peripheral Arterial Vascular Studies
    • Policy number: M.36
    • Summary: Coverage for non-invasive cerebrovascular and peripheral arterial vascular studies follows CMS LCD criteria (L35753, A57592, L35761, A57593) to determine medical necessity for diagnostic imaging.
  • Echocardiogram, Transthoracic (TTE) and Transesophageal (TEE)
    • Policy number: M.37
    • Summary: Echocardiogram coverage is based on InterQual criteria, with PA required for TEE but not for TTE, ensuring appropriate use for cardiac evaluation.
  • Percutaneous Coronary Intervention (PCI)
    • Policy number: M.38
    • Summary: PCI procedures are covered when meeting CMS LCD L34761 criteria for medical necessity in coronary artery disease treatment.
  • Category III Codes
    • Policy number: M.39
    • Summary: Category III procedures are generally considered experimental or not medically necessary unless proven safe, effective, and consistent with accepted medical standards.
  • Physical Medicine and Rehabilitation
    • Policy number: M.40
    • Summary: Continued physical therapy beyond 12 visits requires prior authorization and documentation showing functional improvement, medical necessity, and inability to perform therapy independently.
  • Prostate Rectal Spacers
    • Policy number: M.41
    • Summary: Covers prostate rectal spacers (e.g., SpaceOAR) for patients with localized prostate cancer undergoing hypofractionated radiation therapy when strict clinical criteria are met; not medically necessary if criteria are not met.

MA revised policies effective March 1, 2026

  • Bioengineered Skin and Soft Tissue Substitutes
    • Policy number: M.3
    • Summary: Covers bioengineered skin substitutes for diabetic foot ulcers, venous leg ulcers, and certain reconstructive or burn indications when strict LCD criteria and approved product lists are met; all other uses and products are considered non-covered.
  • MA Cosmetic and Reconstructive Surgery (Codes Added)
    • Policy number: M.5
    • Summary: Adds new codes for cosmetic and reconstructive procedures; coverage follows NCD 250.5, NCD 140.2, and LCD 39051 criteria for medical necessity.
  • MA Cosmetic and Reconstructive Surgery (Tissue Transfer Flaps)
    • Policy number: M.5
    • Summary: Adds tissue transfer flap codes; coverage determined using InterQual criteria for reconstructive surgery indications.
  • MA Radiology
    • Policy number: M.13
    • Summary: Radiology procedures require PA and follow InterQual, NCD, and LCD criteria for specific codes, including nuclear medicine and advanced imaging.
  • MA Procedures Following NCD, LCD or InterQual
    • Policy number: M.15
    • Summary: Adds genetic testing, behavioral therapy, and device codes; coverage based on NCD and LCD guidelines for medical necessity.
  • Evolent Joint Surgeries
    • Policy number: (No M-number provided)
    • Summary: Joint surgery codes require prior authorization, managed by Evolent, for hip, knee, and shoulder procedures.

Commercial new policies effective March 9, 2026

  • Non‑Urgent Air Ambulance Transport
    • Policy number: I.217
    • Summary: Requires preauthorization for planned air ambulance transfers and is covered only when the patient needs acute inpatient care unavailable at the originating facility, the nearest capable receiving facility is used, and no safer lower‑intensity transport option (ground or commercial air) is appropriate; transports for convenience are not medically necessary.

Commercial revised policies effective Feb. 15, 2026

  • Computed Tomography Angiography (CTA)
    • Policy number: IV.62
    • Summary: The use of noninvasive fractional flow reserve following a positive coronary computed tomography angiography (75580) may be considered medically necessary to guide decisions about the use of invasive coronary angiography in individuals with stable chest pain at intermediate risk of coronary artery disease (i.e., suspected or presumed stable ischemic disease). All other uses are considered investigational.
  • Bone Mineral Density Measurement
    • Policy number: IV.78
    • Summary: Screening for osteoporosis using Quantitative Computed Tomography (QCT) (77078), Ultrasound Densitometry and/or Vertebral Fracture Densitometry (77085, 77086, 76777) are Investigational.
  • Amniotic Membrane and Amniotic Fluid
    • Policy number: I.200
    • Summary: The use of amniotic membrane using the following products **(Affinity®, AmnioBand® Membrane, Biovance®, EpiCord®, EpiFix®, Grafix™, NuShield®) is considered scientifically validated for treating specific conditions. These include diabetic lower extremity ulcers, neurotrophic keratitis, corneal ulcers or melts, pterygium repair, Stevens-Johnson syndrome of the eye, persistent epithelial defects, and chronic venous ulcers that have not healed after more than four weeks of standard therapy.
  • Bioengineered Skin and Soft Tissue Substitutes
    • Policy number: I.202
    • Summary: The use of bioengineered skin and soft tissue substitutes is considered scientifically validated for the following indications:
      • Breast reconstruction (including each of the following: AlloDerm®, Cortiva® [AlloMax™], DermACELL™, DermaMatrix™, FlexHD®, FlexHD® Pliable™) OR
      • Diabetic lower extremity ulcers (AlloPatch®a, Apligraf®, Dermagraft®, Integra® Omnigraft™ Dermal Regeneration Matrix (also known as Omnigraft™), and Integra Flowable Wound Matrix, mVASC®, TheraSkin®) OR
      • Venous insufficiency lower extremity ulcers (Apligraf®, Oasis™ Wound Matrix) OR
      • Dystrophic epidermolysis bullosa (OrCel™ (for the treatment of mitten-hand deformity when standard wound therapy has failed and when provided in accordance with the humanitarian device exemption [HDE] specifications of the U.S. Food and Drug Administration [FDA]) OR
      • Second- or third-degree burns (Epicel® (for the treatment of deep dermal or full-thickness burns comprising a total body surface area ≥30% when provided in accordance with the HDE specifications of the FDA), Integra® Dermal Regeneration Template.
  • Oscillatory Devices for Respiratory Disorders
    • Policy number: VII.35
    • Summary: High-frequency chest wall oscillation and oscillatory PEP devices are covered for cystic fibrosis, primary ciliary dyskinesia, and bronchiectasis; all other uses, including Volara device, are investigational.
  • Surgeries for Obstructive Sleep Apnea
    • Policy number: III.62
    • Summary: Covers unilateral hypoglossal nerve stimulation (e.g., Inspire®) for adults and adolescents with Down syndrome under strict clinical criteria; bilateral hypoglossal nerve stimulation (e.g., Genio Device) is considered investigational.

Notifications about medical policy updates can be found under the “Recent Updates” section on the Alerts and Updates page.

Sign up for NaviNet

Registration is free; all you need is a Federal Tax ID. All participating BCBSNE health care and dental providers can enroll for access. 
 
If your office is already using NaviNet, please contact your Security Officer to create a NaviNet account for you. If you do not have a NaviNet account, please visit Register.NaviNet.net to begin the registration process. 

Medicare Advantage

Provider announcement: Removal of MA auto-approval for SNF admissions

Effective March 1, 2026, BCBSNE will be discontinuing the auto-approval process for skilled nursing facility (SNF) admissions for Medicare Advantage (MA) participating (PAR) providers. This change follows prior updates communicated in December 2024 and August 2025 regarding the auto-approval policy.

What’s changing

  • Auto-approval for SNF admissions will no longer be available beginning March 1, 2026.
  • All SNF admissions will require prior authorization for the initial stay and any subsequent days.

What providers need to do

  • Submit prior authorization requests for all SNF admissions starting March 1, 2026
    • Preferred method: PAR providers should submit via NaviNet
    • Non-PAR/out-of-state providers: Refer to the preauthorization page on NaviNet for instructions
  • Continue to provide required clinical documentation to support medical necessity
  • Ensure timely submission to avoid delays in member care
  • Note: Medicare Advantage fax lines are available; however, it is encouraged to submit electronically when possible.

Important reminders

  • The current auto-approval process (three-day auto-approval for PAR SNFs) remains in effect until Feb. 28, 2026
  • Swing bed stays remain ineligible for auto-approval and require prior authorization

Thank you for your attention and collaboration as we implement this updated process.  

Medicare Advantage Update: Discontinued Services Billing and Reimbursement

Effective Jan. 1, 2026, BCBSNE will align its Medicare Advantage billing and reimbursement policy for discontinued procedures with the commercial policy.

When a physician or other qualified health care professional elects to terminate a surgical or diagnostic procedure due to extenuating circumstances, append modifier 53 to the procedure code. This modifier indicates the procedure was started but not completed.

Reimbursement details:

  • Professional discontinued procedures will be reimbursed at 50% of the allowable unmodified amount
  • Multiple procedure reductions still apply when applicable

Please ensure your billing teams are aware of this update and adjust claims accordingly.

Medical: Commercial and FEP

Streamlined preauthorization process is in effect as of Jan. 1, 2026, under LB77

Starting Jan. 1, 2026, providers can submit certain preventive services without prior authorization when billed with eligible preventive diagnosis codes. These claims undergo retrospective review to confirm medical policy criteria are met.

Medical policies included in this streamlined process:

  • BRCA testing (Med Policy V.59)
  • CT colonography (Med Policy I.129)
  • Breast MRI (Med Policy IV.81)

Medical policies are updated to reflect these changes, and documentation is included within the policies.

For complete details, please view the updated medical policies.

Verify Benefits Before Using ABNs

Before presenting an Advanced Beneficiary Notice (ABN) to a member, providers must verify benefits with BCBSNE or the member’s plan. ABNs should not be used for services that are covered, as this can lead to unnecessary costs and member abrasion. Covered services vary by plan, so confirming benefits is essential before presenting an ABN. 

When an ABN Is Required 
An ABN or waiver must be signed before services are rendered if the service may be denied as not medically necessary, investigative or not scientifically validated. Providers must also inform the members in writing of potential financial liability and estimated costs. 

For Federal Employee Program (FEP) members, a signed ABN is mandatory. Documentation in medical records will not be accepted. 

Balance Billing Is Prohibited
In-network providers cannot balance bill BCBSNE members for amounts beyond the BCBSNE allowance for covered services. 
For complete details, review policy GP-X-006: Hold Harmless and Balance Billing.

Policy Update: Non-Urgent Air Ambulance Transport

Policy Number: I.217
Effective Date: March 1, 2026
BCBSNE is committed to ensuring medically necessary care while reducing unnecessary costs. As part of this commitment, preauthorization will be required for all planned, non-urgent air ambulance transfers beginning March 1, 2026.

When Air Ambulance Transport Is Covered

  • The patient requires acute inpatient care that is not available at the originating facility
  • The transfer is to the nearest capable receiving facility
  • No safer, lower-intensity transport option—such as ground ambulance or commercial air travel — is appropriate for the patient’s condition

Important Update

We have contacted all PAR air ambulance providers and advised them to request prior authorization before initiating non-urgent air transport. This step ensures compliance with policy requirements and helps prevent delays or non-covered services.

For additional details, please review the Happening Now article posted Dec. 8, 2025.

Reminder: Partnering for better outcomes: Preparing for GLP-1 preauthorization

As shared in our November 2025 Happening Now update, BCBSNE values our partnership with providers in delivering safe, effective care. GLP-1 medications can play an important role in treatment plans, but successful prior authorization starts with following evidence-based guidelines and medical policy requirements. Taking the right steps upfront helps members access care faster and reduces administrative delays.

Steps for a successful GLP-1 request

  1. Verify coverage and PDL status
    Before submitting an authorization request, confirm that GLP-1 medications are covered under the member’s plan and listed on the Preferred Drug List (PDL). Not all BCBSNE plans cover GLP-1s for weight loss or include these medications on the formulary. If these medications are covered for weight loss, the member must complete at least three months of dietary changes and behavioral modifications before a GLP-1 request can be considered. 

  2. Review the medical policy
    Start by confirming the requested medication meets BCBSNE criteria. Complete details are available in Medical Policy 532. Reviewing the policy ensures compliance with FDA-approved indications and avoids unnecessary denials.

  3. Document lifestyle interventions
    Include evidence of at least three months of dietary changes and behavioral modifications. These steps are required by policy and support sustainable health outcomes

  4. Verify FDA-approved use
    Ensure the medication is prescribed for an approved indication. This supports safe prescribing practices and helps prevent delays.

  5. Gather complete clinical documentation
    Include medical history, diagnostic results, and evidence of lifestyle changes. Complete documentation speeds up reviews and reduces back-and-forth.

Why these steps matter
Following these steps ensures members receive care that is clinically appropriate and effective. It minimizes administrative delays, improves member satisfaction and supports better health outcomes. BCBSNE medical policies are designed to align with current clinical guidelines and evidence-based standards.

Quick-reference checklist for providers

  • Verify coverage and PDL status
  • Review Medical Policy 532
  • Confirm three months of documented lifestyle changes
  • Verify FDA-approved indication
  • Submit complete clinical documentation 

Quality and Risk

Top HCC Documentation & Coding Trends for 2026

As of 2026, CMS is fully phasing in the updated 2024 CMS-HCC (V28) risk adjustment model for Medicare Advantage, replacing the prior blended approach. This new model reshapes condition categories, removes or remaps thousands of ICD-10 codes, and generally results in leaner risk scores, making precise documentation more important than ever. PACE organizations will continue to see blended scoring for now, but all others should expect payment calculations based entirely on the new model.

Providers should note that many previously mapped codes no longer contribute to risk scores, while others require greater specificity (e.g., diabetes with complications vs. without). Using outdated or nonspecific codes may lead to missed HCC capture. Documentation must also be supported by encounter or claim submissions, as CMS no longer accepts diagnoses captured only through chart reviews.

Common pitfalls include under-documenting chronic conditions, failing to capture disease severity or complications and relying on deprecated codes. To avoid these, providers should review updated ICD-10 to HCC mapping files, ensure EMR picklists are current and focus on documenting conditions to their highest level of specificity. Regular chart audits, pre-visit planning and strong collaboration with coding teams can also help close risk gaps and reduce audit exposure.

In short, success under the 2026 model depends on accurate, specific documentation and proactive coding practices. By staying current with CMS updates and avoiding common errors, providers can protect revenue integrity while ensuring that patients’ true health complexity is fully represented.

Congestive Heart Failure (CHF): Accurate Documentation for Chronic Care Management and Risk Adjustment

Congestive Heart Failure (CHF) remains one of the most common and costly chronic conditions in the United States, with significant implications for patient outcomes and risk adjustment accuracy. Proper documentation and coding are essential not only for quality reporting but also for ensuring patients receive the comprehensive care they need.

  1. Capture the Correct Type and Severity
    CHF is not a one-size-fits-all diagnosis. To support accurate coding and reflect true disease burden, providers should specify:
    • Type: Systolic, diastolic or combined
    • Chronicity: Acute, chronic or acute on chronic
    • Laterality (if applicable): Right, left or unspecified
      This level of detail supports selection of the most specific ICD-10-CM code (e.g. I50.22 – Chronic systolic heart failure) and ensures appropriate HCC capture (HCC 85).
       
  2. Link CHF to Underlying or Related Conditions
    When clinically supported, document associated conditions such as hypertension, coronary artery disease or chronic kidney disease. Example:
     
    “Chronic systolic heart failure due to hypertensive heart disease with CKD stage 3b.”
     Linking these diagnoses paints a complete clinical picture, demonstrates medical complexity and ensures that interrelated chronic conditions are reflected accurately in coding and risk adjustment.
     
  3. Document Stability or Progression at Every Visit
    CHF should be assessed and documented at each encounter, even if stable. Indicate whether the condition is compensated or decompensated and describe the patient’s symptom status (e.g., NYHA class). For example:
     
        “Chronic diastolic heart failure, NYHA class II, stable on current medications.”
    Ongoing assessment shows active management and supports continuity of care for this high-risk population.
     
  4. Ensure Medication and Treatment Consistency
    Documentation should align with therapy. Mentioning medications such as beta-blockers, ACE inhibitors/ARBs or diuretics helps validate the diagnosis and treatment plan. Include details on any recent hospitalizations, diagnostic studies or specialist involvement to reinforce management intensity.
     
  5. Why It Matters
    Accurate CHF documentation affects more than coding — it drives patient-centered care, supports appropriate reimbursement through HCC 85 and impacts performance in value-based contracts. Thorough documentation also ensures care teams have the information needed to prevent avoidable readmissions and improve quality outcomes.

Key Takeaway:
Providers play a vital role in closing documentation gaps for chronic conditions like CHF. Clear, specific and consistent documentation ensures accurate HCC capture, reflects the patient’s true disease burden and promotes better outcomes across the continuum of care.

Dental

Dental services under medical benefits: What you need to know

We’re here to help dental providers navigate claim filing when services are covered under a member’s medical benefit plan. Whether it’s oral appliances for sleep apnea or orthodontic billing, we’ve compiled key policies and tips to make the process smoother.

Highlights include:

  • When and how to use the CMS 1500 form
  • Preauthorization requirements for oral appliances
  • Billing guidance for orthodontics and Invisalign
  • Paper claim submission standards
  • GRID and GRID Plus network details

Why this matters:

Clear, accurate claim submissions help ensure timely reimbursement and reduce administrative delays. We want our dental partners to feel confident and supported when providing care to BCBSNE members.

Simplifying dental claim filing with CMS 1500

Dental services covered under medical benefits must be submitted using the CMS 1500 form. To avoid delays, include all required details—especially dental codes starting with “D,” tooth numbers, and supply descriptions. Legible handwritten claims are accepted, and blank forms are available for download.

Oral appliances for sleep apnea: What providers need to know

BCBSNE supports oral appliance therapy for sleep apnea when medically necessary. Dentists play a key role in evaluating and fitting these devices. Be sure to:

  • Submit preauthorization
  • Use CDT codes from the NEtwork BLUE dental fee schedule
  • File claims on the CMS 1500 form

Visit our medical policy site for full details.

Orthodontic billing made easy
Whether you're billing for traditional braces or Invisalign, BCBSNE’s orthodontic policy allows flexible billing:

  • Initial banding: Up to one-third of the total charge
  • Ongoing treatment: Monthly or quarterly billing options

This approach helps streamline reimbursement and ensures clarity for providers.

Dental paper claim submission

To help ensure timely and accurate processing of dental paper claims, please use ADA forms from 2012 or newer. For 2016 and newer forms, be sure to include the member ID in Form Locator 15. 

Mail all claims to:

Blue Cross and Blue Shield of Nebraska
P.O. Box 3248
Omaha, NE 68180-0001

Claims submitted on outdated forms will be returned. For guidance on submitting medical services provided by a dentist using the CMS 1500 form, refer to the Filing Dental Charges on a CMS 1500 document, which outlines the minimum required information.

GRID and GRID+ networks

When credentialed with BCBSNE Network Blue PPO Dental, providers are automatically added to GRID and GRID+. These networks use the same fee schedule and claims process as Network Blue PPO Dental.

This newsletter serves as an amendment to your agreement as a contracting Blue Cross and Blue Shield of Nebraska health care provider and affects your contractual relationship with us.
NaviNet® is a healthcare provider portal providing services for Blue Cross and Blue Shield of Nebraska.
Blue Cross and Blue Shield of Nebraska is an independent licensee of the Blue Cross Blue Shield Association. The Blue Cross Blue Shield Association licenses Blue Cross and Blue Shield of Nebraska to offer certain products and services under the Blue Cross® and Blue Shield® brand names within the state of Nebraska.

Shop Plans
Member Support
Partner Resources
About Us